- Home
- FCFS vs JAZZ Comparison
FCFS vs JAZZ Comparison
Compare FCFS & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCFS
- JAZZ
- Stock Information
- Founded
- FCFS 1988
- JAZZ 2003
- Country
- FCFS United States
- JAZZ Ireland
- Employees
- FCFS N/A
- JAZZ N/A
- Industry
- FCFS Other Specialty Stores
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- FCFS Consumer Discretionary
- JAZZ Health Care
- Exchange
- FCFS Nasdaq
- JAZZ Nasdaq
- Market Cap
- FCFS 5.4B
- JAZZ 6.1B
- IPO Year
- FCFS 1991
- JAZZ 2007
- Fundamental
- Price
- FCFS $121.44
- JAZZ $102.78
- Analyst Decision
- FCFS Strong Buy
- JAZZ Strong Buy
- Analyst Count
- FCFS 4
- JAZZ 13
- Target Price
- FCFS $135.67
- JAZZ $187.15
- AVG Volume (30 Days)
- FCFS 369.5K
- JAZZ 1.6M
- Earning Date
- FCFS 04-24-2025
- JAZZ 04-30-2025
- Dividend Yield
- FCFS 1.25%
- JAZZ N/A
- EPS Growth
- FCFS 19.38
- JAZZ 41.75
- EPS
- FCFS 5.73
- JAZZ 8.65
- Revenue
- FCFS $3,388,514,000.00
- JAZZ $4,068,950,000.00
- Revenue This Year
- FCFS $2.49
- JAZZ $7.60
- Revenue Next Year
- FCFS $5.47
- JAZZ $3.43
- P/E Ratio
- FCFS $21.19
- JAZZ $11.88
- Revenue Growth
- FCFS 7.51
- JAZZ 6.12
- 52 Week Low
- FCFS $100.24
- JAZZ $95.49
- 52 Week High
- FCFS $133.64
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- FCFS 55.93
- JAZZ 31.87
- Support Level
- FCFS $118.92
- JAZZ $100.42
- Resistance Level
- FCFS $122.36
- JAZZ $104.12
- Average True Range (ATR)
- FCFS 4.80
- JAZZ 6.41
- MACD
- FCFS -0.26
- JAZZ -1.27
- Stochastic Oscillator
- FCFS 36.91
- JAZZ 22.51
About FCFS FirstCash Holdings Inc.
FirstCash Holdings Inc operates pawn stores in the United States and Latin America. Its primary business involves making small loans secured by personal property. The the company has three reportable segments: U.S. pawn; Latin America pawn; and Retail POS payment solutions (AFF). It derives majority revenue from U.S. Pawn segment. These pawn loans give the borrower the option of either repaying the loans with interest or forfeiting the property without further penalty. Geographically operates in USA, Mexico, Latin America, with maximum revenue from USA.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.